Skip to main content

Table 5 Relative risks of death within 5 years according to clinicopathological factors and membranous ezrin expression in the entire cohort and in patients with bladder cancer

From: Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker

 

Entire cohort

Bladder

  

Unadjusted

Adjusted

 

Unadjusted

Adjusted

 

n (events)

HR (95% CI)

HR (95% CI)

n (events)

HR (95% CI)

HR (95% CI)

Age

      

Continuous

263 (80)

1.05 (1.01-1.08)

1.03 (0.999-1.07)

258 (80)

1.05 (1.01-1.08)

1.03 (0.998-1.07)

Gender

      

Female

81 (23)

1.00

1.00

78 (23)

1.00

1.00

Male

182 (57)

1.10 (0.68-1.79)

0.94 (0.56-1.58)

180 (57)

1.06 (0.65-1.73)

0.91 (0.54-1.54)

Stage

      

Ta

114 (15)

1.00

1.00

112 (15)

1.00

1,00

T1

84 (22)

2.40 (1.24-4.62)

1.86 (0.86-4.02)

81 (22)

2.47 (1.28-7.68)

2.38 (1.23-4.60)

T2-4

65 (43)

8.83 (4.88-15.97)

5.46 (2.41-12.36)

65 (43)

8.68 (4.80-15.70)

7.12 (3.87-13.08)

Grade

      

Low

133 (20)

1.00

1.00

129 (20)

1.00

1.00

High

130 (60)

4.02 (2.43-6.68)

1.44 (0.71-2.92)

129 (60)

3.94 (2.37-6.54)

1.33 (0.65-2.73)

Smoking

      

Regularly

93 (30)

1.00

1.00

92 (30)

1.00

1.00

Occasionally

15 (4)

0.76 (0.27-2.17)

0.90 (0.31-2.58)

15 (4)

0.75 (0.26-2.14)

0.90 (0.31-2.57)

Former

113 (32)

0.86 (0.52-1.42)

0.73 (0.44-1.21)

110 (32)

0.88 (0.53-1.44)

0.74 (0.45-1.23)

Never

42 (14)

1.04 (0.55-1.95)

1.22 (0.64-2.33)

41 (14)

1.05 (0.56-1.99)

1.26 (0.66-2.39)

Ezrin

      

High

112 (20)

1.00

1.00

111 (20)

1.00

1.00

Low

151 (60)

2.51 (1.52-4.17)

1.69 (1.00-2.85)

147 (60)

2.58 (1.55-4.28)

1.74 (1.03-2.95)